Cardiogenetics

A single positive result here is rarely just one person's diagnosis.

Order a hereditary cancer panel and the result belongs mostly to the patient in front of you. Order a cardiogenetic panel and a positive result opens a conversation about first-degree relatives, cascade testing, and family members who have never set foot in your clinic. A low-confidence variant doesn't just sit in one chart — it can end up driving testing decisions across a whole family tree.

Curated validity, not a wide net

ScreenMyGene's cardiogenetic panel content is curated against established gene-disease validity frameworks, keeping recommendations aligned to genes and conditions with recognized clinical significance rather than every gene that's ever been associated with a cardiac finding in the literature. In a category where a result can ripple outward to people who never asked for it, "technically detectable" and "clinically actionable" need to stay two different bars.

How it works for cardiogenetics specifically

1. Presentation and history extraction — Documented cardiac findings, personal history, and family history relevant to inherited cardiac conditions are pulled from the chart.

2. Gene-disease validity filtering — Candidate genes are filtered against curated validity frameworks before being considered for a panel recommendation.

3. Condition-aligned panel matching — The qualifying panel is matched to the specific inherited cardiac condition supported by the documented presentation.

4. ICD-10 and coverage check — The recommendation is anchored to a documented, matching diagnosis code and checked against Medicare LCD/NCD coverage policy.

What this catches that a broad-panel approach misses

• Presentations where a broad cardiac gene panel would surface variants of uncertain relevance, versus a curated set aligned to established validity
• Family history patterns consistent with an inherited arrhythmia or cardiomyopathy syndrome that a purely symptom-based review might not connect
• Cases where the documented presentation supports a specific condition-aligned panel rather than a generic cardiac genetic testing order

Who this is for

• Medical directors who need a defensible, auditable basis for a result that may drive family-wide cascade testing conversations
• Genetic counselors managing the downstream implications of a cardiogenetic result across relatives
• Molecular labs and cardiology practices standardizing panel selection against current gene-disease validity